Bruce Robinson, MD, PhD & Francesco Lucarelli
Beyond the Trip: Psychedelics in Modern Medicine—Efficacy, Commercialization, and AI Applications
C1 substances show significant efficacy in numerous DSM-5 diagnosed disorders: GAD, MDD, PTSD, and autism. Herein, we meta-analyze current randomized clinical trial findings and their target pathologies. Addressed are the hurdles to acceptance and commercialization, including AI applications.